Situações clínicas que condicionam RCV na categoria imediatamente superior
Utente socialmente desfavorecido;
Utente sedentário e com obesidade central;
Utente com familiar direto portador de DCV diagnosticada e prematura (< 55 anos no sexo masculino e < 65 anos no sexo feminino);
Utente com diminuição da função renal (TGF < 60 ml/min/1.73 m2);
Utente com nível de HDL < 40 mg/dl no homem, < 45 mg/dl na mulher, com TG > 150 mg/dl, aumento do fibrinogénio, da apolipoproteína B e da lipoproteína (a), especialmente em combinação com hipercolesterolemia familiar;
Utente assintomático com evidência de atero sclerose subclínica, por exemplo, a presença de placas ou aumento da espessura íntima-média carotídea ou um índice baixo tornozelo-braço.
Referências bibliográficas
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18;499-502. PubMed ID: 4337382
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
DGS. Norma nº 005/2013 de 19/03/2013 atualizada 21/01/2015
Catapano AL. Graham I. De Backer G. Wiklund O. Chapman MJ. Drexel H. et al. 2016. ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016:37(39):2999-3058.
Society E, France MIC. Backer GG De. Ference BA, Kingdom U, Irelané IMG, et al. 2019 ESC / EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dysipidaemias of the. 2019:1-78.
Ballantyne CM, Hour J. Notarbartolo A. Melani L, Lipka L. Suresh R. etal Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind tral. Circulation, 2003:107(19):2409-15.
Davidson MH, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka Let al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlied. blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004;58(8):746-55.
Ballantyne CM, Hoogeveen RC, Raya JL. Cain VA, Palmer MK, Karlson BW, et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs sirmastatin 40 or 80 mg plus.
Kim KKS. Won Y, Rha YS, Kwak SHC. Kim W. Effect of fixed: «dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe), Wiley Cardiovasc Ther.2016;34:371-82.
Bays HE. Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM, et al. Safety and Efficacy of Ezetimibe Added on to Rosuvastatin 5 or 10 mg Versus Up-Titration of Roswrastatin in Patients With Hypercholesterolemia (the ACTE Study). Am J.